中国帕金森病药物治疗行业市场规模测算逻辑模型 头豹词条报告系列

Investment Rating - The report provides a positive investment rating for the Parkinson's disease drug treatment industry in China, indicating growth potential and market opportunities [1]. Core Insights - The Parkinson's disease drug treatment market in China is projected to grow from CNY 41.34 billion in 2018 to CNY 54.28 billion by 2028, with a compound annual growth rate (CAGR) of approximately 2.66% [3][7]. - The early-stage Parkinson's disease patient drug treatment market is expected to increase from CNY 10.32 billion in 2018 to CNY 13.55 billion by 2028, reflecting a steady growth trend [7]. - The late-stage Parkinson's disease patient drug treatment market is anticipated to grow from CNY 31.02 billion in 2018 to CNY 40.72 billion by 2028, indicating a significant market opportunity [7]. - The prevalence of Parkinson's disease among the population aged 60 and above is projected to rise from 1.35% in 2018 to 1.42% by 2028, highlighting the increasing demand for treatment [11][12]. - The proportion of patients receiving drug treatment remains high at 96.1% throughout the forecast period, indicating strong adherence to treatment protocols [20]. Summary by Sections Market Size - The overall market size for Parkinson's disease drug treatment in China is expected to reach CNY 54.28 billion by 2028, with a steady growth rate observed over the years [7]. - The early-stage patient treatment market is projected to grow to CNY 13.55 billion by 2028, while the late-stage market is expected to reach CNY 40.72 billion [7]. Population Statistics - China's total population is projected to remain relatively stable, with slight fluctuations from 140.54 million in 2018 to 140.44 million by 2028 [8]. - The proportion of the population aged 60 and above is expected to increase from 17.9% in 2018 to 22.36% by 2028, indicating a growing elderly demographic that may require Parkinson's disease treatment [10]. Patient Statistics - The number of Parkinson's disease patients is projected to increase from 339.62 million in 2018 to 445.92 million by 2028, reflecting a growing patient base [16]. - The percentage of early-stage patients remains constant at 53.1% throughout the forecast period, indicating a stable patient distribution [18]. Treatment Penetration - The drug treatment penetration rate among Parkinson's disease patients is expected to remain high at 96.1%, suggesting effective treatment adherence [20]. Drug Treatment Costs - The annual cost of Levodopa treatment is projected to remain stable at approximately CNY 294.71 per patient throughout the forecast period [25]. - The annual cost for dopamine receptor agonists is also expected to remain constant at CNY 105 per patient [28]. Drug Treatment Proportions - The proportion of patients using Levodopa is expected to remain at 40%, while dopamine receptor agonists will account for 35% of the treatment regimens [22][27].